Drug · Small Molecule

Oxaliplatin

CI-DRUG-00000425Explore in graph →NCIt C1181 CHEMBL414804 CIViC Approved

Regulatory

Approvals (26)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory26 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as OXALIPLATIN INJECTION, USP (DIN 02458403) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Jul 13, 2022	health-canada-dpd
CA Health Canada	—	Marketed in Canada as OXALIPLATIN INJECTION, USP (DIN 02457423) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 31, 2022	health-canada-dpd
CA Health Canada	—	Marketed in Canada as TARO-OXALIPLATIN (DIN 02449692) under ATC L01XA03 OXALIPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Sep 18, 2024

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 19 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	327	162	241	1,206	26	CA, US	Aug 7, 2009	1998-01
Malignant Colon Neoplasm	Approved	Phase 3	13	5	15	51	2	US	Aug 7, 2009	1999-11
Malignant Gastric Neoplasm	Phase4	Phase 4	72	33	44	201	0	—	—	1998-04
Malignant Esophageal Neoplasm	Phase4	Phase 4	20	11	14	74	0

Curated evidence

Clinical evidence (22)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–22 of 22 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
MSH3 K383fs1
7-Ethyl-10-Hydroxycamptothecin

Clinical trials

Trials with this intervention (1,219)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1,201–1,219 of 1,219 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00350961	Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma	completed	Phase 1 / Phase 2	39	Rigshospitalet, DenmarkOTHER	1	Aug 26, 2008	clinicaltrials
NCT00351195	Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)	terminated	Phase 2

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: 04ZR38536J
Aliases: 1-OHP, [(1R,-2R)-1,2-cyclohexanediamine-N,N'][oxalato (2--)-O,O']platinum, ACT OXALIPLATIN, Aiheng, Ai Heng, Dacotin, DACPLAT, Diaminocyclohexane Oxalatoplatinum, Eloxatin, ELOXATIN, Eloxatine, Elplat, JM 83, JM-83, JM83, L-OHP, MBP-426 (LIPOSOMAL OXALIPLATIN), NSC-266046, Oxalato (1R,2R-cyclohexanediamine)platinum(II), Oxalatoplatin, Oxalatoplatinum, Oxalato (trans-l-1,2-diaminocyclohexane)platinum(II), Oxaliplatin, Oxaliplatin component of folfox, Oxaliplatin component of xelox, Oxaliplatine, Oxaliplatino, PMS-OXALIPLATIN, RP 54780, RP-54780 … (+10)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (45)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XA03	OXALIPLATIN
DIN (Health Canada)	02296268

ERBB2 R678Q1

Oxaliplatin

Gastric Adenocarcinoma

Predictive

Supports Resistance

accepted

EID13138

In a retrospective cohort of gastric or gastroesophageal junction adenocarcinoma (n = 3116; ERBB2 R678Q n = 40), ERBB2 R678Q was associated with reduced response to oxaliplatin-based regimens compared… (full text at CIViC)

PMID 40699829 · Suzuki et al., 2025 · Open in CIViC

BRAF V600E4
Bevacizumab + Capecitabine + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2121 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, and bevacizumab, those with BRAF V600E mutations had reduced progression-free survival (5.9mo vs. 12.2mo, P=… (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic
Bevacizumab + Capecitabine + Cetuximab + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	submitted	EID8646 In a study of metastatic colorectal cancer patients treated with capecitabine, oxaliplatin, bevacizumab, and cetuximab those with BRAF V600E mutations had reduced progression-free survival (6.6mo vs. … (full text at CIViC) PMID 19571295 · Tol et al., 2009 · Open in CIViC	civic
Cetuximab + Encorafenib + Fluorouracil + Leucovorin + OxaliplatinCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Sensitivity Response	5	submitted	EID13309 In the randomized phase 3 BREAKWATER trial, previously untreated patients with BRAF V600E-mutated metastatic colorectal cancer receiving first-line encorafenib, cetuximab, and mFOLFOX6 (n=236) had sig… (full text at CIViC) PMID 40444708 · Elez et al., 2025 · Open in CIViC	civic
Oxaliplatin	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID2117 Of 100 metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy, the 6 patients with either BRAF V600E or D594K had reduced progression-free survival compared to 94 pati… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic